FAQ on NanoViricides' NV-387 as a Potential Treatment for Measles Outbreaks
Summary
NanoViricides, Inc. highlights its drug candidate NV-387 as a potential treatment for the increasing measles outbreaks in the U.S., Canada, the UK, and EU, noting its safety in animal studies and Phase I clinical trial, and its potential for Orphan Drug and Fast Track designations.
What is NV-387 and who is developing it?
NV-387 is a broad-spectrum antiviral drug candidate developed by NanoViricides, Inc., a clinical-stage company specializing in antiviral therapies using nanomedicine technology.
Why is NV-387 considered a potential treatment for measles?
NV-387 has shown effectiveness and safety in animal studies and completed a Phase I clinical trial with no adverse events, indicating strong tolerability in humans, at a time when measles cases are rising and there is no approved drug for measles.
How does NV-387 work?
NV-387 is based on NanoViricides’ nanoviricide technology, which uses host-mimetic nanomaterials to target and neutralize viruses, though the specific mechanism of action against measles is not detailed in the provided content.
What are the benefits of NV-387 receiving Orphan Drug and Fast Track designations?
These designations could accelerate NV-387’s approval process and offer seven years of market exclusivity, providing a faster pathway to addressing the critical medical need for a measles treatment.
Where are the measles outbreaks occurring that NV-387 could address?
Measles outbreaks are increasing in the United States, Canada, the UK, and the European Union, with the U.S. reporting 1,319 cases in 2025 and Europe reporting 127,350 cases in 2024.
What is the current status of NV-387 in clinical development?
NV-387 has completed a Phase I clinical trial with no adverse events and is being prepared for Phase II human clinical trials, focusing on its use against RSV, COVID-19, influenza, and other respiratory viral infections, as well as MPOX/Smallpox.
How does NV-387 compare to existing treatments for measles?
There are currently no approved drugs for the treatment of measles, making NV-387 a potentially groundbreaking treatment option, especially in areas with low vaccination rates or among individuals with immune dysfunction.
Who can I contact for more information about NanoViricides and NV-387?
For more information, visit NanoViricides’ website at www.NanoViricides.com or check the latest news and updates at https://ibn.fm/NNVC.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 127027